Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
The goal was creating a single molecule that could activate both receptors
A comprehensive medical history is essential to identify contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as GLP-1 agonists carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies
5,19 Like any medication, GLP-1RAs may have side effects, including nausea, vomiting, diarrhea, and injection site reactions
Pt A, Dec
Before she could do this she needed to synthesise different GLP-1 fragments (peptides) in large quantities which she did with the assistance of her technician
US$ 29.28
US$ 28.15
US$ 28.98
US$ 27.91
US$ 22.46
US$ 26.09
US$ 28.82
US$ 26.52
